News and Trends 30 May 2023 UK invests £650M in life sciences A £650 million ($804 million) war-chest to boost the U.K.’s life sciences sector has been announced. The ‘Life Sci for Growth’ package brings together 10 different policies including £121 million ($150 million) to improve commercial clinical trials to bring new medicines to patients faster, up to £48 million ($59.4 million) of new money for scientific […] May 30, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2023 PharmEnable raises $7.5M to develop small molecule drugs to treat cancer and neurological diseases PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi […] May 25, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 AMR research gets £39m shot from UK government Research initiatives to develop new treatments to tackle antimicrobial resistance (AMR) – known as the “silent killer” – will receive a cash injection of up to £39 million ($48.5 million) from the U.K. government’s Global AMR Innovation Fund (GAMRIF). However, according to the director of Global Health Policy and Senior Policy Fellow at the Center […] May 23, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2023 Take part in a clinical trial? Sure, just pay me The majority of people in the U.K. (68%) would consider taking part in a clinical trial, it has been revealed today, while half of Brits would also be willing to take part in an early phase clinical trial. Financial payment is the most popular motivation for taking part in a clinical trial, but discovering new […] May 23, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 Industry responds to UK science strategy launch The UK Health Security Agency’s (UKHSA) has launched a 10-year science strategy, setting out how science can save more lives and contribute to the U.K.’s ambition of being a global science superpower. The strategy sets out how the UKHSA scientific capabilities – including genomics, vaccine evaluation, surveillance, data science, diagnostics and toxicology – will be […] May 18, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2023 Sania Therapeutics launches to advance neural circuit dysfunction medicines Sania Therapeutics, which develops genetic medicines for neural circuit dysfunction, has launched with the unveiling of its platforms at the American Society of Gene & Cell Therapy (ASGCT) conference. Sania Therapeutics’ approach combines the evolution of adeno-associated viruses (AAV) in human neural circuits, the fundamental components of the nervous system, and tuneable conditionally-activated ion channels. […] May 18, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 May 2023 LabGenius looks to create molecules with huge increase in tumor killing ability LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’ T-cell engager (TCE) lead optimization platform, which delivered highly potent and efficacious single-domain antibodies with best-in-class killing selectivity. Optimizing antibody therapeutics across multiple properties is […] May 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2023 Achilles Therapeutics’ new platform identifies most potent T-cell antigens Achilles Therapeutics plc says its newly-developed AI application, trained with proprietary real-world data, outperformed current AI and non-AI methods for neoantigen immunogenicity prediction in a recent analysis, enabling the identification of the most potent clonal neoantigens for personalized cancer therapies. Further details of the company’s AI-powered PELEUS bioinformatics platform are expected to be presented at […] May 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2023 5 highlights at first Genomics and Precision Medicine Expo Genomics and Precision Medicine Expo – taking place on May 23 and 24 2023 at ExCeL London – has announced its top 5 highlights for this year’s inaugural conference. The event, which is being run in partnership with Genomics England, will explore the latest advancements and developments in genome sequencing and genomic testing, and the […] May 12, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Apr 2023 Six synthetic biology companies that have made a mark The consequences of the climate crisis coupled with soil degradation and its impact on food and water security, seem dire. But, as ambitious as it may sound, synthetic biology companies could alleviate some of the environmental burden that the planet faces. As it involves the redesigning of organisms by genetically engineering them to have new, […] April 28, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 26 Apr 2023 aVaxziPen’s needle-free vaccine yields positive data across multiple diseases aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, presented data at the World Vaccine Congress (WVC) in Washington, U.S., recently. The company presented a poster entitled, “Needle-free, injectable solid dose vaccine delivery generates equivalent immune response with different antigens and animal models.” The company said immunogenicity data from four in vivo models […] April 26, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2023 LifeArc launches £40M funding call to create Translational Rare Disease Centres LifeArc is inviting applications from academic institutions for its latest £40 million ($49.8 million) initiative to fund four or five new Translational Rare Disease Centres in the U.K., along with a separate co-ordinating hub. LifeArc, which is a self-funded, non-profit medical research charity, specializes in early-stage translation – the advancement of scientific discoveries towards patient […] April 24, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email